Navigation Links
Rutgers, UMDNJ receive $23 million to develop antidotes for chemical weapons attacks
Date:9/13/2011

The National Institutes of Health (NIH) has awarded a five-year $23.2 million grant to a group of investigators at Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School to continue their research aimed at developing drug products that could be used against chemical warfare agents from a terrorist attack.

Members of the Environmental and Occupational Health Sciences Institute (EOHSI), Rutgers and UMDNJ-Robert Wood Johnson Medical School have been collaborating with scientists from the School of Public Health at New York Medical College and the Chemistry Department at Lehigh University for the past five years to devise therapies that could be used if deadly chemical poisons were released into the general population.

The focus of the research is the development of drugs to treat individuals exposed to mustard gas. The newly awarded funding allows these investigators who are part of the UMDNJ/Rutgers CounterACT Research Center of Excellence the opportunity to continue work begun in 2006 after the NIH granted Rutgers and UMDNJ-Robert Wood Johnson Medical School $19.2 million to establish the center and begin its research.

"This funding allows our us to continue our considerable efforts with different research groups to develop drug products that can be used successfully against a chemical terrorist attack," said Jeffrey Laskin, Professor of Environmental and Occupational Medicine at Robert Wood Johnson Medical School, and director of the center. "This is critical to preventing serious injury and death from any such attack."

The focus of the center's research is the development of drug products to treat individuals exposed to mustard gas, which causes symptoms ranging from skin irritations and conjunctivitis to severe ulcerations, blistering of the skin, blindness and irreversible damage to the respiratory tract and lungs. Mustard gas was first used by the German military against Allied troops during World War I and more recently in the Iran-Iraq conflict during the 1980s. It is easy to make and transport and is still considered a high risk terrorist threat.

"We were asked if we could apply our expertise to help address this type of national security issue," said Laskin. "There has been a lot of conversation over the years about the problems that could result from a terrorist attack and everyone realized that we needed to develop a therapy to counteract this if it happens."

The principal investigators in the UMDNJ/Rutgers CounterACT Research Center of Excellence include Director Jeffrey Laskin of UMDNJ, Co-Director Donald Gerecke at Rutgers Ernest Mario School of Pharmacy, Marion Gordon, Debra Laskin and Patrick Sinko, also at Rutgers School of Pharmacy, Diane Heck at New York Medical College, and Ned Heindel at Lehigh University. They work closely with Batelle Laboratory in Ohio, where mustard gas experiments are carried out.


'/>"/>

Contact: Robin Lally
rlally@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Related biology news :

1. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
2. LCC science projects receive $1.2 million through WaterSMART program
3. NJIT professor working with graphene, carbon nanotubes to receive honor
4. Danforth Center Collaborative Research Program receives funding to improve crop yield in Africa
5. Marine Science Institute receives $7 Million grant to study the impact of the Deepwater Horizon
6. UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship
7. Scientists receive grant to develop new DNA sequencing method
8. Hawaii receives funding for liver cancer research
9. CWRU School of Dental Medicine receives $2.6 million in grants
10. Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting
11. MegaMatcher and VeriFinger SDK Fingerprint Compression Algorithms Receive WSQ Certification from FBI Biometric Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):
(Date:5/24/2017)... Austin, TX May 24, 2017 (PRWEB) , ... ... ... Require Constant Connectivity , Medical systems are increasingly being developed with Wi-Fi connectivity ... to be easily moved from room to room. In addition, compact mobile devices ...
(Date:5/23/2017)... , ... May 23, 2017 ... ... an unlimited source of human cardiovascular cells for research and the development ... makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to ...
(Date:5/23/2017)... ... 23, 2017 , ... Vortex Biosciences , provider of circulating tumor cell ... tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The ...
(Date:5/23/2017)... ... , ... Cambridge Semantics , the leading provider of Big Data management ... and Expo in Boston May 23-25 with a featured speaker and solution demos ... Lake is also a finalist for the Best of Show award. , James LaPointe, ...
Breaking Biology Technology: